Search

Conozca cómo los expertos del Ralph Lauren Center de Memorial Sloan Kettering Cancer Center atendieron a Maria cerca de casa.

… Thursday, October 26, 2023 Como profesora jubilada y practicante activa en su iglesia, Maria Tucker sabe bien cuál es el valor de la comunidad. Por eso, cuando le diagnosticaron cáncer de mama en estadio 1 a fines de 2020, sus amigos y familiares de su vecindario en el Bronx se movilizaron para apoyarla

Scientists came to MSK to celebrate the 75th birthday of a leader in the field of structural biology.

… Tuesday, May 16, 2017 Dinshaw Patel Dinshaw Patel Thomas Hermann, University of California San Diego Thomas Hermann, University of California San Diego Lawrence Shapiro, Columbia University Lawrence Shapiro, Columbia University Alexander Serganov, New York University Alexander Serganov, New York University

DeAngelis is acknowledged for her groundbreaking research in the field of neuro-oncology over her more than 30-year career.

… Friday, September 25, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Physician-in-Chief and Chief Medical Officer Lisa M. DeAngelis, MD, is included on Avenue Magazine ’s The Power List 2020 . The list of more than 50 visionaries within the New York metropolitan area comprises leaders

MSK researchers moved cancer science ahead in 2015 with landmark discoveries that suggest new treatment strategies and shed light on how the disease progresses.

… Tuesday, December 29, 2015 Microscopic image of spherical cluster of cells, most of them pink cells with a smaller number of blue ones. Microscopic image of a spherical organoid of intestinal cells. Taken from the blog post "Manipulating a Single Gene Turns Colorectal Cancer Cells Back to Normal." See

Learn how MSK's expertise in metastatic breast cancer helped a mother celebrate a long-awaited milestone with her family.

… Friday, July 12, 2024 When Emma Mon learned the breast cancer she’d been diagnosed with as young mother had returned and spread to her lungs, she feared her time was running out. But that was six years ago, and since then, she’s been living her life with metastatic (or Stage 4) breast cancer . It has

New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.

… Friday, December 20, 2024 In everyday life, when things turn out the opposite of what you expect, it’s usually cause for frustration. In science, it’s often the starting point for discovery. That’s what happened to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK) and their collaborators

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.

… Monday, June 5, 2023 Researchers from Memorial Sloan Kettering Cancer Center (MSK) revealed new findings about hereditary cancers and genetics at the recent 2023 American Society of Clinical Oncology (ASCO) annual meeting. Genetic mutations that are passed down through families cause a significant percentage

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

… Thursday, April 12, 2007 Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

… Wednesday, March 14, 2012 Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial

Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center for Cancer Care. The 750,000-square-foot, 23-story outpatient cancer center on East 74th Street and FDR Drive is made possible by a landmark gift of $150 million from Mr. Koch, the largest single gift in the history of the institution.

… Thursday, May 11, 2017 Memorial Sloan Kettering Cancer Center (MSK) executives, including longtime board member David Koch, along with construction workers and physicians will all gather today for a “topping off” ceremony to mark completion of the steel construction phase of the David H. Koch Center